Skip to Content

Notice

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Novel Use and Method of Rapamycin To Treat Toxic Shock

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Department of the Army, DoD.

ACTION:

Notice.

SUMMARY:

Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/231,348 entitled “Novel Use and Method of Rapamycin to Treat Toxic Shock,” filed August 5, 2009. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES:

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The invention relates to the use of Rapamycin as a treatment of toxic shock induced by staphylococcal exotoxins; more specifically, staphylococcal enterotoxins that are potent activators for human T cells and can cause lethal shock.

Start Signature

Brenda S. Bowen,

Army Federal Register Liaison Officer.

End Signature End Supplemental Information

[FR Doc. E9-23770 Filed 10-1-09; 8:45 am]

BILLING CODE 3710-08-P